GlassScriptPhysician profile
Sarah A Kampfer
NPI 1922618750
$1,052.30
in general payments reported to CMS, 2019-2025
23 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.74 · 2022: $117 · 2023: $122 · 2024: $385 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $224.71 | 2022-2025 | |
| Novo Nordisk INC | $210.71 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $90.93 | 2023-2025 | Airsupra, Breztri |
| Abbott Laboratories | $68.90 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $68.56 | 2023-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.37 | 2025 | Ofev |
| Glaxosmithkline, LLC. | $35.45 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $34.12 | 2023-2024 | |
| Dexcom, INC. | $32.81 | 2025 | Dexcom G6 Transmitter |
| Olympus America INC. | $27.74 | 2021 | |
| Axsome Therapeutics, INC. | $24.47 | 2025 | Auvelity |
| Exact Sciences Corporation | $20.60 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $19.76 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Sanofi Pasteur INC. | $18.20 | 2024 | |
| Vbi Vaccine (Delaware) INC. | $18.12 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $17.08 | 2024 | Veozah |
| Currax Pharmaceuticals LLC | $16.75 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.42 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $15.59 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.68 | 2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $14.09 | 2023 | Camzyos |
| Lilly USA, LLC | $14.00 | 2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Kampfer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.